磷脂酰乙醇在脂肪性肝病中的应用
综述指出脂肪性肝病(SLD)分型依赖准确评估饮酒,传统自报存在偏倚,磷脂酰乙醇(PEth)是特异性反映近期饮酒的血检标志物,检测窗口可达4周。建议将PEth与自报饮酒及AUDIT-C问卷三角互证以改善SLD亚类分型,并系统评估了PEth的生化基础、药代动力学、伦理与临床应用。
要点
- PEth仅在乙醇存在时形成,对近期饮酒高度特异,检测窗口可达4周。
- 解读PEth需考虑饮酒模式、全血与干血斑检测差异及患者特征。
- 建议PEth联合自报饮酒与AUDIT-C问卷三角互证,改善SLD亚类分型。
核心结论
- PEth可补充自报饮酒的不足,联合自报与AUDIT-C问卷可改善SLD亚类分型并捕捉低估。
研究设计与样本
- 综述,系统评估PEth的生化基础、药代动力学、伦理影响与临床使用。
主要发现
- PEth仅在乙醇存在时形成,对近期饮酒高度特异,检测窗口可达4周。
- 自报饮酒因污名与回忆偏倚可导致低估,客观生物标志物因此必要。
- 准确解读PEth需考虑饮酒模式、全血与干血斑检测差异及患者特征。
关键数值与推荐
- 推荐将PEth测量与自报饮酒及AUDIT-C问卷结合进行饮酒评估三角互证。
临床怎么用
- 在SLD亚类分型中,将PEth与自报饮酒和AUDIT-C问卷联合使用以捕捉低估并处理报告与客观测量间的差异。
局限性
- 解读PEth需注意影响血酒精浓度与PEth代谢的多种因素,包括饮酒模式、检测基质与患者特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Steatotic liver disease (SLD) encompasses metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), and their combination (MetALD). Distinguishing these subclasses relies on accurately assessing current alcohol intake, particularly as subclass-specific drug therapies become available. Traditionally, clinicians have relied on self-reported alcohol intake, but stigma and recall bias can lead to underestimation. Objective biomarkers complementing self-reporting are therefore essential. Phosphatidylethanol (PEth), a blood-based biomarker formed exclusively in the presence of ethanol, has emerged as highly specific for recent alcohol intake, offering a detection window of up to 4 weeks. However, accurate interpretation of PEth measurements requires awareness of various factors influencing blood alcohol concentration and PEth metabolism including drinking pattern, measurement in whole blood vs. dried blood spots and patient characteristics. To improve SLD subclassification, we recommend triangulating the alcohol intake assessment by combining PEth measurements with self-reported alcohol intake and the AUDIT-C questionnaire. This approach can capture underestimation, provides more granular insight into alcohol use, and addresses discrepancies between patient-report and objective alcohol measurements. This review critically evaluates the biochemical basis, pharmacokinetics, ethical implications, and the clinical use of PEth. We highlight its potential to improve both patient care and research in hepatology. Finally, we discuss current unmet needs and future developments that could ultimately support the broader, evidence-based integration of PEth into clinical medicine.
引用
- Torp N, Israelsen M, Thiele M, et al. Phosphatidylethanol in steatotic liver disease. J Hepatol. 2025. PMID: 40759197. doi:10.1016/j.jhep.2025.07.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。